BUDGET IMPACT ANALYSIS OF TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN ADULT PATIENTS WITH BARICITINIB IN THE RUSSIAN FEDERATION

被引：0
|
作者：
Yagudina, R. [1 ]
Kulikov, A. [1 ]
Serpik, V [1 ]
Protsenko, M. [1 ]
机构：
[1] Sechenov Univ, Sechenov First Moscow State Med Univ, Moscow, Russia
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY13
引用
收藏
页码：S903 / S903
页数：1
相关论文
共 50 条
  • [21] BUDGET IMPACT ANALYSIS OF BELIMUMAB IN THE TREATMENT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN RUSSIAN FEDERATION
    Kulikov, A.
    Komarov, I
    Pochuprina, A.
    VALUE IN HEALTH, 2014, 17 (07) : A525 - A526
  • [22] SERIOUS INFECTION AND ASSOCIATED RISK FACTORS IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB
    Winthrop, K. L.
    Genovese, M. C.
    Harigai, M.
    Chen, L.
    Dickson, C. L.
    Hyslop, D. L.
    Nishikawa, A.
    Bradley, J. D.
    Dougados, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 158 - 158
  • [23] Effect of Baricitinib on Joint-Related Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis
    Thudium, Christian S.
    Bay-Jensen, Anne C.
    Cahya, Suntara
    Dow, Ernst R.
    Karsdal, Morten A.
    Koch, Alisa E.
    Zhang, Wenling
    Benschop, Robert J.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [24] BUDGET IMPACT OF BARICITINIB FOR PATIENTS WITH SEVERE ALOPECIA AREATA
    Fenske, C.
    Rosettie, K.
    Lu, T.
    Ferrufino, C.
    Borns, M.
    Johnson, N.
    Morrow, P.
    VALUE IN HEALTH, 2022, 25 (07) : S397 - S398
  • [25] BUDGET IMPACT ANALYSIS OF GOLIMUMAB IN ADULT RHEUMATOID ARTHRITIS PATIENTS IN KINGDOM OF SAUDI ARABIA
    Al Jedai, A.
    AL-Mudaiheem, H.
    Pathak, P.
    Awad, N.
    Mohamed, O.
    Alghanim, N.
    Hussain, W.
    Qamar, A.
    Alama, T.
    VALUE IN HEALTH, 2019, 22 : S47 - S47
  • [26] NEW STRATEGIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS IN ITALY: A BUDGET IMPACT ANALYSIS
    Iannazzo, S.
    Giuliani, G.
    Zaniolo, O.
    Sacchi, V
    Pradelli, L.
    VALUE IN HEALTH, 2008, 11 (06) : A540 - A540
  • [27] Microarray Pathway Analysis Comparing Baricitinib and Adalimumab in Moderate to Severe Rheumatoid Arthritis Patients, from a Phase 3 Study
    Emery, Paul
    Taylor, Peter C.
    Weinblatt, Michael
    Tanaka, Yoshiya
    Keystone, Edward C.
    Dow, Ernst R.
    Higgs, Richard
    Macias, William L.
    Rocha, Guilherme
    Rooney, Terence P.
    Schlichting, Douglas E.
    Zuckerman, Steven H.
    McInnes, Iain B.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [28] A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis
    Schlueter, Max
    Rouse, Peter
    Pitcher, Ashley
    Graham-Clarke, Peita Louise
    Nicolay, Claudia
    Fakhouri, Walid
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (02) : 221 - 228
  • [29] BUDGET IMPACT ANALYSIS OF CANACINUMAB IN THE TREATMENT OF PATIENTS WITH MUCKLE-WELLS SYNDROME IN THE RUSSIAN FEDERATION
    Yagudina, R.
    Kulikov, A.
    Pochuprina, A.
    VALUE IN HEALTH, 2015, 18 (07) : A663 - A663
  • [30] BUDGET IMPACT ANALYSIS OF TOFACITINIB IN THE TREATMENT OF MODERATE RHEUMATOID ARTHRITIS AFTER FAILURE OF DMARDS IN GUATEMALA IN 2015
    Peralta-Acon, M.
    Chavez-Perez, N.
    VALUE IN HEALTH, 2016, 19 (03) : A229 - A229
12345